HALO Halozyme Therapeutics
- 43.150
- -0.690-1.57%
- 43.150
- 0.0000.00%
Halozyme Therapeutics News
Halozyme Therapeutics Price Target Cut to $71.00/Share From $72.00 by JMP Securities
Halozyme Therapeutics Price Target Cut to $71.00/Share From $72.00 by JMP Securities
Halozyme Therapeutics Is Maintained at Market Outperform by JMP Securities
Halozyme Therapeutics Is Maintained at Market Outperform by JMP Securities
J.P. Morgan Securities: Maintaining the Halozyme Therapeutics (HALO.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $72.00 to $71.00.
J.P. Morgan Securities: Maintaining the Halozyme Therapeutics (HALO.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $72.00 to $71.00.
JMP Securities Maintains Market Outperform on Halozyme Therapeutics, Lowers Price Target to $71
JMP Securities analyst Jason Butler maintains Halozyme Therapeutics with a Market Outperform and lowers the price target from $72 to $71.
Halozyme Therapeutics Currently Up Six Consecutive Days, On Track for Longest Winning Streak Since December 2022 -- Data Talk
Halozyme Therapeutics, Inc. (HALO) is currently at $43.10, up $1.89 or 4.59% --Would be highest close since Aug. 29, 2023, when it closed at $43.10 --On pace for largest percent increase since Feb.
Halozyme to Participate in Upcoming Investor Conferences
SAN DIEGO, May 8, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present and host investor
Halozyme Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Halozyme Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
HC Wainwright & Co. : The Halozyme Therapeutics (HALO.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $50.00.
HC Wainwright & Co. : The Halozyme Therapeutics (HALO.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $50.00.
Halozyme Therapeutics Inc (HALO) (Q1 2024) Earnings Call Transcript Highlights: Robust Growth ...
Halozyme Therapeutics Q1 2024 Earnings: Misses EPS Estimates but Shows Revenue Growth
Halozyme Therapeutics Shares Are Trading Higher Following Mixed Q1 Results.
Halozyme Therapeutics Shares Are Trading Higher Following Mixed Q1 Results.
Halozyme Reiterates FY24 Guidance: Sees Total Revenue $915M-$985M Vs $951.47M Est., Adj. EPS $3.55-$3.90 Vs $3.68 Est.
Halozyme Reiterates FY24 Guidance: Sees Total Revenue $915M-$985M Vs $951.47M Est., Adj. EPS $3.55-$3.90 Vs $3.68 Est.
Halozyme Therapeutics Q1 2024 Adj EPS $0.79 Beats $0.69 Estimate, Sales $195.879M Miss $199.777M Estimate
Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $0.79 per share which beat the analyst consensus estimate of $0.69 by 14.49 percent. The company reported quarterly sales of $195.87
GUIDANCE: (HALO) HALOZYME THERAPEUTICS Sees Fiscal Year 2024 Revenue Range $915M - $985M
04:18 PM EDT, 05/07/2024 (MT Newswires) -- GUIDANCE: (HALO) HALOZYME THERAPEUTICS Sees Fiscal Year 2024 Revenue Range $915M - $985M
Earnings Flash (HALO) HALOZYME THERAPEUTICS Posts Q1 Revenue $195.9M, Vs. Street Est of $199.7M
04:18 PM EDT, 05/07/2024 (MT Newswires) -- Earnings Flash (HALO) HALOZYME THERAPEUTICS Posts Q1 Revenue $195.9M, vs. Street Est of $199.7M
Halozyme Therapeutics | 10-Q: Quarterly report
Press Release: HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS PR Newswire SAN DIEGO, May 7, 2024 Revenue Increased 21% YOY to $196 million; Net Income of $77 million; Adjusted EBITDA of $116
Halozyme Therapeutics 1Q EPS 60c >HALO
Halozyme Therapeutics 1Q EPS 60c >HALO
Expert Ratings For Halozyme Therapeutics
Halozyme Therapeutics (NASDAQ:HALO) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The table below provides a snapshot of t
FDA Accepts Bristol Myers Application for Injected Opdivo
The FDA has accepted Bristol-Myers (NYSE:BMY) biologics license application for a subcutaneous formulation of its oncology drug Opdivo, also known as nivolumab, with a target action date of Feb. 28.
Analysis
Price Target
No Data
